Drug
Ezogabine clinical trials
Also written Retigabine, GKE-841, D-23129 and Potiga.
- studies test it
- 23
- open now
- 0
- in phase 3
- 12
- first study started
- 2005
How studies write it
Studies that test it under each name
Brand
Other names
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2012 (7)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 7 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 12
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Epilepsy
- 15
Who runs them
Industry 19 · Other 4
GlaxoSmithKline (16) · Xenon Pharmaceuticals Inc. (2) · James Murrough (1) · Brian Wainger (1) · Icahn School of Medicine at Mount Sinai (1) · Bausch Health Americas, Inc. (1) · University Hospital of Mont-Godinne (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ezogabine is read from its arms, and is right about nine times in ten.
Testing it · 23
- An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEETerminatedPhase 3Xenon Pharmaceuticals Inc.NCT04912856Written as XEN496
- XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyTerminatedPhase 3Xenon Pharmaceuticals Inc.NCT04639310Written as XEN496
- Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset SeizuresTerminatedPhase 4GlaxoSmithKlineNCT01721317Written as Ezogabine/Retigabine IR
- An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset SeizuresTerminatedPhase 4GlaxoSmithKlineNCT01607346Written as ezogabine/retigabine
- Study in Pediatric Subjects With EpilepsyTerminatedPhase 2GlaxoSmithKlineNCT01494584Written as ezogabine/retigabine
- Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGSTerminatedPhase 3GlaxoSmithKlineNCT01668654Written as retigabine/ezogabine
- Study to Treat Major Depressive Disorder With a New MedicationCompletedPhase 2James MurroughNCT03043560Written as Ezogabine
- Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind TrialCompletedPhase 3GlaxoSmithKlineNCT00310375Written as Ezogabine: USAN Retigabine (International Nonproprietary Name)
- A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset SeizuresCompletedPhase 3GlaxoSmithKlineNCT01777139Written as Retigabine IR
- Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)CompletedPhase 3GlaxoSmithKlineNCT01336621Written as Retigabine IR
- Clinical Trial of Ezogabine (Retigabine) in ALS SubjectsCompletedPhase 2Brian WaingerNCT02450552Written as Ezogabine
- Study to Treat Major Depressive Disorder (MDD) With a New MedicationCompletedPhase 2Icahn School of Medicine at Mount SinaiNCT02149836Written as ezogabine
- Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097TerminatedPhase 3GlaxoSmithKlineNCT00310388Written as Retigabine (INN), Ezogabine (USAN)
- Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian SubjectsWithdrawnPhase 1GlaxoSmithKlineNCT01691872Written as Retigabine
- Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset SeizuresTerminatedPhase 3GlaxoSmithKlineNCT01648101Written as Retigabine 900mg/day
- Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese SubjectsCompletedPhase 1GlaxoSmithKlineNCT01462669Written as 50mg Ezogabine/retigabine
- An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be AssessedCompletedPhase 1GlaxoSmithKlineNCT01583036Written as Digoxin + Retigabine
- Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl MetaboliteCompletedPhase 1GlaxoSmithKlineNCT01480609Written as Retigabine / Ezogabine
- Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)CompletedPhase 2Bausch Health Americas, Inc.NCT00612105Written as Retigabine
- Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in EpilepsyCompletedPhase 3GlaxoSmithKlineNCT00235755Written as Retigabine
Codes
What other systems call ezogabine · ClinicalTrials.gg INT003936
- MeSH (NLM) C101866ezogabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 12G01I6BBUEZOGABINEConfirmed FDA, NLM, Wikidata
- RxNorm 1112990Confirmed FDA, Wikidata
- Wikidata Q2146170ezogabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72839EzogabineOne source FDA
- DrugBank DB04953One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C101866 | ezogabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 12G01I6BBU | EZOGABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1112990 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2146170 | ezogabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72839 | Ezogabine | One source FDA |
| DrugBank | DB04953 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.